Cefazolin plasma protein binding and its covariates in neonates

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 12, 2012, Pages 3359-3365

  Smits, A ^a   Kulo, A ^a,b   Verbesselt, R ^a   Naulaers, G ^a   De Hoon, J ^a   Vermeersch, P ^a   Allegaert, K ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CEFAZOLIN; PLASMA PROTEIN; SANDOZ; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ARTICLE; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; GESTATIONAL AGE; HUMAN; HYPERBILIRUBINEMIA; INFANT; NEWBORN; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; WILCOXON SIGNED RANKS TEST;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; BLOOD PROTEINS; CEFAZOLIN; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PLASMA; PROTEIN BINDING; TIME FACTORS;

EID: 85027958860     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1703-x     Document Type: Article

References (23)

1. Allegaert K, van Mieghem T, Verbesselt R, Vanhole C, Devlieger R, Cossey V, Deprest J, de Hoon J (2009) Cefazolin plasma protein binding saturability during pregnancy. Methods Find Exp Clin Pharmacol 31(1):25-28
2. Hemels MA, van den Hoogen A, Verboon-Maciolek MA, Fleer A, Krediet TG (2011) A seven-year survey of management of coagulase-negative staphylococcal sepsis in the neonatal intensive care unit: vancomycin may not be necessary as empiric therapy. Neonatology 100(2):180-185
3. Caloza DL Jr, Semar RW, Bernfeld GE (1979) Intravenous use of cephradine and cefazolin against serious infections. Antimicrob Agents Chemother 15(1):119-122 (Pubitemid 9099641)
4. Decroix MO, Zini R, Chaumeil JC, Tillement JP (1988) Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs. Biochem Pharmacol 37(14):2807-2814
5. Koshida R, Nakashima E, Ichimura F, Nakano O, Watanabe R, Taniguchi N, Tsuji A (1987) Comparative distribution kinetics of cefazolin and tobramycin in children. J Pharmacobiodyn 10(9):436- 442 (Pubitemid 18051505)
6. Grandison MK, Boudinot FD (2000) Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 38(3):271-290 (Pubitemid 30156625)
7. Vella-Brincat JW, Begg EJ, Kirkpatrick CM, Zhang M, Chambers ST, Gallagher K (2007) Protein binding of cefazolin is saturable in vivo both between and within patients. Br J Clin Pharmacol 63 (6):753-757 (Pubitemid 46753567)
8. Douglas A, Udy AA, Wallis SC, Jarrett P, Stuart J, Lassig-Smith M, Deans R, Roberts MS, Taraporewalla K, Jenkins J, Medley G, Lipman J, Roberts JA (2011) Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother 55(11):5238-5242
9. van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, van Ramshorst B, Vlaminckx B, Deneer VH, Knibbe CA (2011) Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol 67 (10):985-992
10. Palmer GM, Atkins M, Anderson BJ, Smith KR, Culnane TJ, McNally CM, Perkins EJ, Chalkiadis GA, Hunt RW (2008) I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 101(4):523-530
11. Clinical and Laboratory Standards Institute (CLSI) (2012) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. M100-S22, vol 32, no 3:74
12. Deguchi Y, Koshida R, Nakashima E, Watanabe R, Taniguchi N, Ichimura F, Tsuji A (1988) Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts. J Pharm Sci 77(8):674-678 (Pubitemid 19030290)
13. Notarianni LJ (1990) Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 18(1):20-36 (Pubitemid 20040336)
14. Nerli B, Romanini D, Picó G (1997) Structural specificity requirements in the binding of beta lactam antibiotics to human serum albumin. Chem Biol Interact 104(2-3):179-202 (Pubitemid 27263373)
15. Ichimura F, Matsushita R, Tsuji A, Deguchi Y (1990) Mutual interaction between bilirubin and cefazolin in binding to human serum albumin. J Pharm Sci 79(11):1041-1042 (Pubitemid 20376204)
16. Pullen J, Stolk LM, Degraeuwe PL, van Tiel FH, Neef C, Zimmermann LJ (2007) Protein binding of flucloxacillin in neonates. Ther Drug Monit 29(3):279-283 (Pubitemid 47262256)
17. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U (2011) Protein binding: do we ever learn? Antimicrob Agents Chemother 55(7):3067-3074
18. Schmidt S, Gonzalez D, Derendorf H (2010) Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99(3):1107-1122
19. Gravenstein D, Suri A, Derendorf HC, Koska AJ (1998) Influence of plasma expansion on plasma protein binding of ketorolac. J Clin Anesth 10(6):464-468 (Pubitemid 28467137)
20. Kosaka T, Hosokawa K, Shime N, Taniguchi F, Kokufu T, Hashimoto S, Fujiwara H, Yaku H, Sugioka N, Okada K, Fujita N (2012) Effects of renal function on the pharmacokinetics and pharmacodynamics of prophylactic cefazolin in cardiothoracic surgery. Eur J Clin Microbiol Infect Dis 31(2):193-199
21. Soltys BJ, Hsia JC (1977) Fatty acid enhancement of human serum albumin binding properties. A spin label study. J Biol Chem 252 (12):4043-4048 (Pubitemid 8114422)
22. Omar F, van der Watt G, November V, Pillay TS (2010) Plasma free fatty acid reference interval in South African neonates in the first week of life. Ann Clin Biochem 47(Pt 4):381-382
23. Jeevanandam M, Hsu YC, Ramias L, Schiller WR (1989) A rapid, automated micromethod for measuring free fatty acids in plasma/serum. Clin Chem 35(11):2228-2231 (Pubitemid 20004700)